{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:42:55Z","timestamp":1793400175288,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s12013-024-01337-2","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:03:48Z","timestamp":1717589028000},"page":"2275-2283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Iguratimod Alleviates Experimental Sj\u00f6gren\u2019s Syndrome by Inhibiting NLRP3 Inflammasome Activation"],"prefix":"10.1007","volume":"82","author":[{"given":"Qi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Rui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"8","key":"1337_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.12968\/hmed.2017.78.8.438","volume":"78","author":"I Thorne","year":"2017","unstructured":"Thorne, I., & Sutcliffe, N. (2017). Sj\u00f6gren\u2019s syndrome. British Journal of Hospital Medicine, 78(8), 438\u2013442.","journal-title":"British Journal of Hospital Medicine"},{"issue":"1","key":"1337_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/14397595.2018.1546268","volume":"29","author":"T Odani","year":"2019","unstructured":"Odani, T. & Chiorini, J. A. (2019). Targeting primary Sj\u00f6gren\u2019s syndrome. Modern Rheumatology, 29(1), 70\u201386.","journal-title":"Modern Rheumatology"},{"issue":"2","key":"1337_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5114\/reum.2018.75521","volume":"56","author":"J Perzy\u0144ska-Mazan","year":"2018","unstructured":"Perzy\u0144ska-Mazan, J., Ma\u015bli\u0144ska, M., & Gasik, R. (2018). Neurological manifestations of primary Sj\u00f6gren\u2019s syndrome. Reumatologia, 56(2), 99\u2013105.","journal-title":"Reumatologia"},{"key":"1337_CR4","doi-asserted-by":"publisher","first-page":"107219","DOI":"10.1016\/j.intimp.2020.107219","volume":"90","author":"CH Li","year":"2021","unstructured":"Li, C. H., Ma, Z. Z., Jian, L. L., Wang, X. Y., Sun, L., Liu, X. Y., Yao, Z. Q. & Zhao, J. X. (2021). Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-\u03b1 signaling pathways. International Immunopharmacology, 90, 107219.","journal-title":"International Immunopharmacology"},{"key":"1337_CR5","doi-asserted-by":"publisher","first-page":"107563","DOI":"10.1016\/j.intimp.2021.107563","volume":"96","author":"Y Xia","year":"2021","unstructured":"Xia, Y., Fang, X., Dai, X., Li, M., Jin, L., Tao, J., Li, X. & Wang, Y. (2021). Iguratimod ameliorates nephritis by modulating the Th17\/Treg paradigm in pristane-induced lupus. International Immunopharmacology, 96, 107563.","journal-title":"International Immunopharmacology"},{"issue":"8","key":"1337_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/eci.13791","volume":"52","author":"X Xie","year":"2022","unstructured":"Xie, X., Gan, H., Tian, J., Li, F., Chen, J., Wang, J., Liao, J., & Li, S. (2022). Iguratimod inhibits skin fibrosis by regulating TGF-\u03b21\/Smad signalling pathway in systemic sclerosis. European Journal of Clinical Investigation, 52(8), 27.","journal-title":"European Journal of Clinical Investigation"},{"issue":"2","key":"1337_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.55563\/clinexprheumatol\/urhbn0","volume":"39","author":"R Kong","year":"2021","unstructured":"Kong, R., Gao, J., Ji, L., Peng, Y., Zhang, J., & Zhao, D. (2021). Iguratimod ameliorates rheumatoid arthritis progression through regulating miR-146a mediated IRAK1 expression and TRAF6\/JNK1 pathway: an in vivo and in vitro study. Clinical and Experimental Rheumatology, 39(2), 289\u2013303.","journal-title":"Clinical and Experimental Rheumatology"},{"key":"1337_CR8","doi-asserted-by":"publisher","first-page":"114503","DOI":"10.1016\/j.expneurol.2023.114503","volume":"368","author":"Q Wang","year":"2023","unstructured":"Wang, Q., Yi, J., Liu, H., Luo, M., Yin, G., & Huang, Z. (2023). Iguratimod promotes functional recovery after SCI by repairing endothelial cell tight junctions. Experimental Neurology, 368, 114503.","journal-title":"Experimental Neurology"},{"key":"1337_CR9","doi-asserted-by":"publisher","first-page":"107936","DOI":"10.1016\/j.intimp.2021.107936","volume":"99","author":"S Shao","year":"2021","unstructured":"Shao, S., Qu, Z., Liang, Y., Xu, Y., Zhou, D., Li, D., Zhang, Y., & Yin, S. (2021). Iguratimod decreases bleomycin-induced pulmonary fibrosis in association with inhibition of TNF-\u03b1 in mice. International Immunopharmacology, 99, 107936.","journal-title":"International Immunopharmacology"},{"key":"1337_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molimm.2017.10.008","volume":"93","author":"XP Jiang","year":"2018","unstructured":"Jiang, X. P., Huang, X. L., Yang, Z. P., Wang, S. C., Xie, W., Miao, L., Tang, L., & Huang, Z. M. (2018). Iguratimod ameliorates inflammatory responses by modulating the Th17\/Treg paradigm in dextran sulphate sodium-induced murine colitis. Molecular Immunology, 93, 9\u201319.","journal-title":"Molecular Immunology"},{"key":"1337_CR11","doi-asserted-by":"publisher","first-page":"932114","DOI":"10.3389\/fbinf.2022.932114","volume":"2","author":"H Zeng","year":"2022","unstructured":"Zeng, H., Chen, S., Lu, X., & Yan, Z. (2022). Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis. Frontiers in Bioinformatics, 2, 932114.","journal-title":"Frontiers in Bioinformatics"},{"key":"1337_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.993860","volume":"14","author":"Z Long","year":"2023","unstructured":"Long, Z., Deng, Y., He, Q., Yang, K., Zeng, L., Hao, W., Fan, J., & Chen, H. (2023). Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Immunology, 14, 993860. https:\/\/doi.org\/10.3389\/fimmu.2023.993860.","journal-title":"Frontiers in Immunology"},{"key":"1337_CR13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.12998\/wjcc.v10.i4.1286","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang, J., Wang, X., Tian, J. J., Zhu, R., Duo, R. X., Huang, Y. C., & Shen, H. L. (2022). Iguratimod in treatment of primary Sj\u00f6gren\u2019s syndrome concomitant with autoimmune hemolytic anemia: A case report. World Journal of Clinical Cases, 10, 1286\u20131290. https:\/\/doi.org\/10.12998\/wjcc.v10.i4.1286.","journal-title":"World Journal of Clinical Cases"},{"issue":"2","key":"1337_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/03009742.2020.1809701","volume":"50","author":"Q Shao","year":"2021","unstructured":"Shao, Q., Wang, S., Jiang, H., & Liu, L. (2021). Efficacy and safety of iguratimod on patients with primary Sj\u00f6gren\u2019s syndrome: a randomized, placebo-controlled clinical trial. Scandinavian Journal of Rheumatology, 50(2), 143\u2013152.","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"2","key":"1337_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/14397595.2020.1789335","volume":"31","author":"H Chen","year":"2021","unstructured":"Chen, H., Qi, X., Li, Y., Wu, Q., Shi, Q., Wang, L., Li, J., Zhao, L., Zhang, L., Zhou, X., Fei, Y., Liu, J., Su, J., Wu, D., Yang, Y., Jiang, H., Zeng, X., Zhang, F., & Zhao, Y. (2021). Iguratimod treatment reduces disease activity in early primary Sj\u00f6gren\u2019s syndrome: An open-label pilot study. Modern Rheumatology, 31(2), 394\u2013398.","journal-title":"Modern Rheumatology"},{"issue":"1","key":"1337_CR16","doi-asserted-by":"publisher","first-page":"023","DOI":"10.1186\/s13075-023-03109-4","volume":"25","author":"T Lyu","year":"2023","unstructured":"Lyu, T., Jiang, H., Zeng, L., Liu, S., He, C., Luo, C., Qiao, L., Zhao, Y., & Chen, H. (2023). Iguratimod suppresses Tfh cell differentiation in primary Sj\u00f6gren\u2019s syndrome patients through inhibiting Akt\/mTOR\/STAT3 signaling. Arthritis Research & Therapy, 25(1), 023\u201303109.","journal-title":"Arthritis Research & Therapy"},{"key":"1337_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","volume":"41","author":"J Fu","year":"2023","unstructured":"Fu, J., & Wu, H. (2023). Structural mechanisms of NLRP3 inflammasome assembly and activation. Annual Review of Immunology, 41, 301\u2013316.","journal-title":"Annual Review of Immunology"},{"issue":"5","key":"1337_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/joim.12115","volume":"274","author":"C Baldini","year":"2013","unstructured":"Baldini, C., Rossi, C., Ferro, F., Santini, E., Seccia, V., Donati, V., & Solini, A. (2013). The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sj\u00f6gren\u2019s syndrome. Journal of Internal Medicine, 274(5), 480\u2013489.","journal-title":"Journal of Internal Medicine"},{"key":"1337_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cca.2017.09.019","volume":"474","author":"SK Kim","year":"2017","unstructured":"Kim, S. K., Choe, J. Y., & Lee, G. H. (2017). Enhanced expression of NLRP3 inflammasome-related inflammation in peripheral blood mononuclear cells in Sj\u00f6gren\u2019s syndrome. Clinica Chimica Acta, 474, 147\u2013154.","journal-title":"Clinica Chimica Acta"},{"key":"1337_CR20","volume":"2022","author":"J He","year":"2022","unstructured":"He, J., Wang, Y., Xu, L., Xu, C., Zhu, Y., Xu, M., Chen, Y., Guo, L., Hu, W., Xu, D., Jing, R., & Xu, B. (2022). Ruscogenin ameliorated Sj\u00f6gren\u2019s syndrome by inhibiting NLRP3 inflammasome activation. Evidence-Based Complementary and Alternative Medicine, 2022, 6425121.","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"issue":"8","key":"1337_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/1348-0421.13084","volume":"67","author":"J Xu","year":"2023","unstructured":"Xu, J., Shen, Z., Du, Y., Zhang, S., Xi, Y., Zhang, Y., Wang, D., & Zhu, Y. (2023). Huoxue Jiedu recipe represses mitochondrial fission to alleviate submandibular gland inflammation in Sj\u00f6gren\u2019s syndrome. Microbiology and Immunology, 67(8), 377\u2013387.","journal-title":"Microbiology and Immunology"},{"key":"1337_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.746317","volume":"9","author":"M Zhang","year":"2021","unstructured":"Zhang, M., Lei, Y. S., Meng, X. W., Liu, H. Y., Li, L. G., Zhang, J., Zhang, J. X., Tao, W. H., Peng, K., Lin, J., & Ji, F. H. (2021). Iguratimod alleviates myocardial ischemia\/reperfusion injury through inhibiting inflammatory response induced by cardiac fibroblast pyroptosis via COX2\/NLRP3 signaling pathway. Frontiers in Cell and Developmental Biology, 9, 746317.","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"4","key":"1337_CR23","first-page":"10","volume":"126","author":"V Manfr\u00e8","year":"2020","unstructured":"Manfr\u00e8, V., Cafaro, G., Riccucci, I., Zabotti, A., Perricone, C., Bootsma, H., De Vita, S., & Bartoloni, E. (2020). One year in review 2020: Comorbidities, diagnosis and treatment of primary Sj\u00f6gren\u2019s syndrome. Clinical and Experimental Rheumatology, 126(4), 10\u201322.","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"7","key":"1337_CR24","first-page":"980","volume":"20","author":"F Andr\u00e9","year":"2022","unstructured":"Andr\u00e9, F., & B\u00f6ckle, B. C. (2022). Sj\u00f6gren\u2019s syndrome. Journal der Deutschen Dermatologischen Gesellschaft, 20(7), 980\u20131002.","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"1337_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jim.2016.07.003","volume":"437","author":"J Zuo","year":"2016","unstructured":"Zuo, J., Williams, A. E., Park, Y. J., Choi, K., Chan, A. L., Reeves, W. H., Bubb, M. R., Lee, Y. J., Park, K., Stewart, C. M., & Cha, S. (2016). Muscarinic type 3 receptor autoantibodies are associated with anti-SSA\/Ro autoantibodies in Sj\u00f6gren\u2019s syndrome. Journal of Immunological Methods, 437, 28\u201336.","journal-title":"Journal of Immunological Methods"},{"issue":"8","key":"1337_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41374-020-0453-0","volume":"101","author":"H Wu","year":"2021","unstructured":"Wu, H., Chen, X., Gu, F., Zhang, P., Xu, S., Liu, Q., Zhang, Q., Wang, X., Wang, C., K\u00f6rner, H. & Wei, W. (2021). CP-25 alleviates antigen-induced experimental Sj\u00f6gren\u2019s syndrome in mice by inhibiting JAK1-STAT1\/2-CXCL13 signaling and interfering with B-cell migration. Laboratory Investigation, 101(8), 1084\u20131097.","journal-title":"Laboratory Investigation"},{"issue":"9","key":"1337_CR27","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/labinvest.3780149","volume":"80","author":"H Nakamura","year":"2000","unstructured":"Nakamura, H., Kawakami, A., Yamasaki, S., Nakashima, T., Kamachi, M., Migita, K., Kawabe, Y., Nakamura, T., Koji, T., Hayashi, Y., & Eguchi, K. (2000). Expression and function of X chromosome-linked inhibitor of apoptosis protein in Sj\u00f6gren\u2019s syndrome. Laboratory Investigation, 80(9), 1421\u20131427.","journal-title":"Laboratory Investigation"},{"issue":"12","key":"1337_CR28","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s10495-006-0281-8","volume":"11","author":"K Kulkarni","year":"2006","unstructured":"Kulkarni, K., Selesniemi, K., & Brown, T. L. (2006). Interferon-gamma sensitizes the human salivary gland cell line, HSG, to tumor necrosis factor-alpha induced activation of dual apoptotic pathways. Apoptosis, 11(12), 2205\u20132215.","journal-title":"Apoptosis"},{"issue":"1","key":"1337_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/cbin.11236","volume":"44","author":"L Ye","year":"2020","unstructured":"Ye, L., Shi, H., Wu, S., Yu, C., Wang, B., & Zheng, L. (2020). Dysregulated interleukin 11 in primary Sj\u00f6gren\u2019s syndrome contributes to apoptosis of glandular epithelial cells. Cell Biology International, 44(1), 327\u2013335.","journal-title":"Cell Biology International"},{"issue":"6","key":"1337_CR30","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/ddr.21964","volume":"83","author":"L Chang","year":"2022","unstructured":"Chang, L., Kong, A., Guo, Y., Zhang, J., Sun, Y., Chen, P., & Wang, X. (2022). Quercetin ameliorates salivary gland apoptosis and inflammation in primary Sj\u00f6gren\u2019s syndrome through regulation of the leptin\/OB-R signaling. Drug Development Research, 83(6), 1351\u20131361.","journal-title":"Drug Development Research"},{"issue":"10","key":"1337_CR31","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.autrev.2018.05.005","volume":"17","author":"K Psianou","year":"2018","unstructured":"Psianou, K., Panagoulias, I., Papanastasiou, A. D., de Lastic, A. L., Rodi, M., Spantidea, P. I., Degn, S. E., Georgiou, P., & Mouzaki, A. (2018). Clinical and immunological parameters of Sj\u00f6gren\u2019s syndrome. Autoimmunity Reviews, 17(10), 1053\u20131064.","journal-title":"Autoimmunity Reviews"},{"issue":"10","key":"1337_CR32","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","volume":"191","author":"Q Luo","year":"2013","unstructured":"Luo, Q., Sun, Y., Liu, W., Qian, C., Jin, B., Tao, F., Gu, Y., Wu, X., Shen, Y., & Xu, Q. (2013). A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. Journal of Immunology, 191(10), 4969\u20134978.","journal-title":"Journal of Immunology"},{"issue":"51","key":"1337_CR33","doi-asserted-by":"publisher","first-page":"26502","DOI":"10.1074\/jbc.M116.743328","volume":"291","author":"J Bloom","year":"2016","unstructured":"Bloom, J., Metz, C., Nalawade, S., Casabar, J., Cheng, K. F., He, M., Sherry, B., Coleman, T., Forsthuber, T., & Al-Abed, Y. (2016). Identification of iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential. Journal of Biological Chemistry, 291(51), 26502\u201326514.","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"1337_CR34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1756-185X.13463","volume":"22","author":"L Zhao","year":"2019","unstructured":"Zhao, L., Mu, B., Zhou, R., Cheng, Y., & Huang, C. (2019). Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9. International Journal of Rheumatic Diseases, 22(4), 686\u2013694.","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"9","key":"1337_CR35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3390\/biology12091217","volume":"12","author":"S Nagata","year":"2023","unstructured":"Nagata, S., Yamasaki, R., Takase, E. O., Iida, K., Watanabe, M., Masaki, K., Wijering, M. H. C., Yamaguchi, H., Kira, J. I., & Isobe, N. (2023). Iguratimod ameliorates the severity of secondary progressive multiple sclerosis in model mice by directly inhibiting IL-6 production and Th17 cell migration via mitigation of glial inflammation. Biology, 12(9), 1217.","journal-title":"Biology"},{"key":"1337_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jaut.2018.02.010","volume":"91","author":"AG Vakrakou","year":"2018","unstructured":"Vakrakou, A. G., Boiu, S., Ziakas, P. D., Xingi, E., Boleti, H., & Manoussakis, M. N. (2018). Systemic activation of NLRP3 inflammasome in patients with severe primary Sj\u00f6gren\u2019s syndrome fueled by inflammagenic DNA accumulations. Journal of Autoimmunity, 91, 23\u201333.","journal-title":"Journal of Autoimmunity"},{"issue":"4","key":"1337_CR37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/imm.13605","volume":"168","author":"J Zhou","year":"2023","unstructured":"Zhou, J., Onodera, S., & Yu, Q. (2023). Inhibition of NLRP3 inflammasome activity by MCC950 leads to exacerbation of Sj\u04e7gren\u2019s syndrome pathologies in non-obese diabetic mice. Immunology, 168(4), 697\u2013708.","journal-title":"Immunology"},{"key":"1337_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113460","volume":"153","author":"W Liu","year":"2022","unstructured":"Liu, W., Han, X., Li, Q., Sun, L., & Wang, J. (2022). Iguratimod ameliorates bleomycin-induced pulmonary fibrosis by inhibiting the EMT process and NLRP3 inflammasome activation. Biomedicine & Pharmacotherapy, 153, 113460.","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"1337_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109455","volume":"119","author":"C Hou","year":"2019","unstructured":"Hou, C., Zhu, X., Shi, C., Peng, Y., Huang, D., Li, Q., & Miao, Y. (2019). Iguratimod (T-614) attenuates severe acute pancreatitis by inhibiting the NLRP3 inflammasome and NF-\u03baB pathway. Biomedicine & Pharmacotherapy, 119, 109455.","journal-title":"Biomedicine & Pharmacotherapy"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-024-01337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-024-01337-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-024-01337-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T10:21:05Z","timestamp":1727778065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-024-01337-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1337"],"URL":"https:\/\/doi.org\/10.1007\/s12013-024-01337-2","relation":{},"ISSN":["1085-9195","1559-0283"],"issn-type":[{"value":"1085-9195","type":"print"},{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"24 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The experimental protocol of our study was performed in accordance with the Guide for the Care and Use of Laboratory Animals and the experimental protocol approved by Shengli Oilfield Central Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}